Pieris Pharmaceuticals Inc (NASDAQ:PIRS) major shareholder Orbimed Advisors Llc sold 1,709,620 shares of Pieris Pharmaceuticals stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $7.35, for a total transaction of $12,565,707.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Orbimed Advisors Llc also recently made the following trade(s):
- On Monday, December 18th, Orbimed Advisors Llc sold 147,635 shares of Pieris Pharmaceuticals stock. The shares were sold at an average price of $5.70, for a total transaction of $841,519.50.
Shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) traded up $0.32 on Thursday, reaching $7.44. 570,141 shares of the company’s stock traded hands, compared to its average volume of 694,200. The firm has a market capitalization of $347.16, a P/E ratio of -10.05 and a beta of 1.79. Pieris Pharmaceuticals Inc has a 52 week low of $1.66 and a 52 week high of $7.90.
Several equities analysts recently issued reports on PIRS shares. HC Wainwright set a $9.00 price objective on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 2nd. ValuEngine lowered shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, BidaskClub raised shares of Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $9.00.
A number of institutional investors and hedge funds have recently made changes to their positions in PIRS. Voya Investment Management LLC acquired a new stake in Pieris Pharmaceuticals in the second quarter valued at approximately $100,000. Wells Fargo & Company MN acquired a new stake in Pieris Pharmaceuticals in the third quarter valued at approximately $105,000. State of Wisconsin Investment Board acquired a new stake in Pieris Pharmaceuticals in the second quarter valued at approximately $132,000. The Manufacturers Life Insurance Company boosted its stake in Pieris Pharmaceuticals by 1,106.3% in the second quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock valued at $161,000 after acquiring an additional 29,150 shares in the last quarter. Finally, Rhumbline Advisers acquired a new stake in Pieris Pharmaceuticals in the second quarter valued at approximately $184,000. Institutional investors own 50.45% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/04/insider-selling-pieris-pharmaceuticals-inc-pirs-major-shareholder-sells-1709620-shares-of-stock.html.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.